Schmidt Arthur, Pickartz Tilman, Lerch Markus M, Fanelli Fabrizio, Fiocca Fausto, Lucatelli Pierleone, Cereatti Fabrizio, Hoffmeister Albrecht, van Steenbergen Werner, Kraft Matthias, Meier Benjamin, Caca Karel
Department of Gastroenterology, Klinikum Ludwigsburg, University of Heidelberg, Germany.
Department of Medicine A, University Medicine Greifswald, Germany.
United European Gastroenterol J. 2017 Apr;5(3):398-407. doi: 10.1177/2050640616663757. Epub 2016 Sep 7.
Temporary placement of removable, fully covered, self-expandable metal stents (fcSEMS) for treatment of benign biliary strictures (BBS) has been reported to be effective. However, the optimal extraction time point remains unclear and stent migration has been a major concern.
The objective of this study was to evaluate the efficacy and safety of this treatment modality using an fcSEMS with a special antimigration design and prolonged stent indwell time.
We performed a prospective, single-arm study at six tertiary care centers in Europe. Patients with BBS underwent endoscopic or percutaneous implantation of an fcSEMS (GORE® VIABIL® Biliary Endoprosthesis, W.L. Gore & Associates, Flagstaff, AZ, USA). The devices were scheduled to be removed nine months later, and patients were to return for follow-up for an additional 15 months.
Forty-three patients were enrolled in the study. Stricture etiology was chronic pancreatitis in the majority of patients (57.5%). All fcSEMS were placed successfully, either endoscopically (76.7%) or percutaneously (23.3%). Stent migration was observed in two patients (5.2%). Primary patency of the SEMS prior to removal was 73.0%. All attempted stent removals were successful. At removal, stricture was resolved or significantly improved without need for further therapy in 78.9% of patients. Stricture recurrence during a follow-up of two years post-implant was observed in two patients.
Temporary placement of the fcSEMS is a feasible, safe and effective treatment for BBS. The design of the device used in this study accounts for very low migration rates and facilitates easy stent retrieval, even after it has been in place for up to 11 months.
据报道,临时放置可移除的、完全覆盖的自膨式金属支架(fcSEMS)治疗良性胆管狭窄(BBS)是有效的。然而,最佳取出时间点仍不明确,支架移位一直是主要问题。
本研究的目的是评估使用具有特殊抗移位设计和延长支架留置时间的fcSEMS这种治疗方式的有效性和安全性。
我们在欧洲的六个三级医疗中心进行了一项前瞻性单臂研究。患有BBS的患者接受了fcSEMS(美国亚利桑那州弗拉格斯塔夫市W.L.戈尔公司的GORE® VIABIL®胆管内支架)的内镜或经皮植入。这些装置计划在九个月后取出,患者需返回进行额外15个月的随访。
43名患者纳入研究。大多数患者(57.5%)的狭窄病因是慢性胰腺炎。所有fcSEMS均成功放置,其中内镜放置占76.7%,经皮放置占23.3%。两名患者(5.2%)观察到支架移位。取出前SEMS的初始通畅率为73.0%。所有尝试的支架取出均成功。取出时,78.9%的患者狭窄得到解决或显著改善,无需进一步治疗。两名患者在植入后两年的随访中出现狭窄复发。
临时放置fcSEMS是一种治疗BBS可行、安全且有效的方法。本研究中使用的装置设计使得移位率极低,即使在支架放置长达11个月后也便于轻松取出。